SCHEMBL7122115

SCHEMBL7122115

OC[C@H]1OC(c2ccc3ccc4cccnc4c3n2)C[C@@H]1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.40
TSHR P16473 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GMNN O75496 1/20 0.40
HSP90AA1 P07900 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
MMP9 P14780 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
MMP8 P22894 1/20 0.40
CCR1 P32246 1/20 0.40
THPO P40225 1/20 0.40
MTOR P42345 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10702398 0.73 PIM1 (0.39) LMNATP53HTTSMN1; SMN2MAPT
SCHEMBL3227328 0.73 PIM1 (0.39) LMNATP53HTTSMN1; SMN2MAPT
SCHEMBL5878277 0.68 CYP2A6 (0.58) SMN1; SMN2CYP3A4
SCHEMBL14533671 0.68 CYP2A6 (0.58) SMN1; SMN2CYP3A4
SCHEMBL14507306 0.68 CYP2A6 (0.58) SMN1; SMN2CYP3A4
SCHEMBL8663124 0.68 ADRB1 (0.38) LMNASMN1; SMN2ADRA1AGALR3NR2F2
SCHEMBL9751247 0.68 ADRB1 (0.38) LMNASMN1; SMN2ADRA1AGALR3NR2F2
SCHEMBL7124527 0.67 GALR3 (0.37) TSHRCYP3A4GALR3NR2F2ADRB1
SCHEMBL24687116 0.66 GALR3 (0.36) TSHRHTTKDM4ECYP3A4CYP2D6
SCHEMBL5048342 0.66 GALR3 (0.36) TSHRHTTKDM4ECYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670193-B2 Coupling with organometallic compound; emission light RESEARCH CORPORATION TECHNOLOGIES, INC. 2003-12-30 US disclosed
US-6479650-B1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same RESEARCH CORPORATION TECHNOLOGIES, INC. 2002-11-12 US disclosed
US-20020160411-A1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2002-10-31 US disclosed
WO-2001044220-A2 FLUORESCENT NUCLEOSIDE ANALOGS AND COMBINATORIAL FLUOROPHORE ARRAYS COMPRISING SAME RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160411-A1 Fluorescent nucleoside analogs and combinatorial fluorophore arrays comprising same DERA, FBL, DUT MMP2 3597/4885TSHR 2933/4885LMNA 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.